1.0Cilcarehttps://www.cilcare.com/jprich600338<blockquote class="wp-embedded-content" data-secret="L0qQoM2K4C"><a href="https://www.cilcare.com/jp/our-missions-external-innovation/in-vivo-studies/">聴覚耐性 & 安全性試験</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.cilcare.com/jp/our-missions-external-innovation/in-vivo-studies/embed/#?secret=L0qQoM2K4C" width="600" height="338" title="“auditory tolerance & safety studies” — Cilcare" data-secret="L0qQoM2K4C" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.cilcare.com/wp-includes/js/wp-embed.min.js </script>auditory tolerance & safety studies Clinical data confirms that many therapeutic compounds, including those targeting indications unrelated to hearing and otic disorders, should be tested for auditory safety. Ototoxicity and associated auditory pathologies may affect millions of patients taking medication, potentially contributing to a diminished quality of life. Additionally, several promising therapeutics and devices are currently in development for improving the lives of more than 500 million people suffering from hearing loss or tinnitus. The auditory safety of these solutions must be tested before being approved by regulatory authorities. CILcare provides unparalleled ototoxicity services that support early-stage development and late-stage safety assessments. We conduct preclinical trials in rodents and larger […]